Rare Daily Staff

France-based CDMO Yposkesi, which specializes in cell and gene therapies, said it launched the the construction of its second commercial cell and gene therapy facility to produce treatments for patients with rare and life-threatening diseases.

The $71 million (€58 million), 50,000 square-foot plant is being constructed adjacent to the company’s existing facility in Corbeil-Essonnes, about 25 miles south of Paris. It will serve as a global resource for cell and gene therapy, providing production capacity for early clinical to commercially available biologics used to treat rare diseases.

With this new state-of-the-art facility, designed for European and American GMP compliance, Yposkesi will double its production footprint to 100,000 square feet. This facility, it said, will address the shortage in manufacturing capacity for drug developers seeking to advance clinical trials and commercialize new therapeutic drugs.

The new facility will also incorporate a centralized warehouse, capacity for media, solutions and mountings preparation as well as drug substance production suites and storage, and quality control lab resources.

In March 2021, global CDMO SK Pharmteco became a majority equity shareholder in Yposkesi.    Project SKY will create approximately 80 new jobs by 2023.

“SKY is the culmination of our industrial strategy, guaranteeing clients a range of quality services from early clinical drug development through all phases to the manufacture of large-scale commercial batches of ATMPs,” said Alain Lamproye, executive chairman of Yposkesi.

Yposkesi’s plant extension is scheduled to be qualified and operational in conformance with EMA and FDA regulations in 2023.

Photo: Alain Lamproye, executive chairman of Yposkesi

X